Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

The acquisition marks a turning point for the company after months of financial uncertainty and data breach concerns.

Announcing the $256 million deal, the New York-based biotech firm vowed to comply with 23andMe’s privacy policy, which was a ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

A Bay Area biotech company that laid off dozens of people this week has blamed the job cuts on policies of the Trump administration. Eikon Therapeutics Inc. cut 55 jobs from its ...

Leveraging Northway Biotech’s 20+ years of CDMO expertise, Kaida BioPharma is advancing KAD101, a targeted therapy for ...

In its announcement of the acquisition, Regeron claimed it would ensure that customers’ personal data including genetic and ...

The Beachwood-based company announced on Tuesday, May 20, that it has appointed Dr. David Llewellyn as its new CEO and as a ...

Chinese biotech company 3SBio's shares surged early Tuesday after its around US$6 billion licensing deal with Pfizer to develop, manufacture and commercialize a promising cancer drug. Shares were up ...

A Philadelphia entrepreneur developing eye repair tech stood out among international contenders as it gears up to raise a ...